In section Market Quotes

Bausch + Lomb’s BL1332 Trial Misses Primary Endpoint

Bausch + Lomb said a Phase 2 trial of BL1332, a treatment for pain following photorefractive keratectomy, did not meet its primary endpoint: a statistically significant reduction in pain intensity 24 hours after surgery.

Bausch + Lomb’s BL1332 Trial Misses Primary Endpoint

Patients who received BL1332 showed numerically greater pain relief across the analysis 72 hours after surgery, the eye-health company said. The treatment was well tolerated.

Bausch + Lomb is completing its analysis of the data and plans to discuss the findings with the Food and Drug Administration, including potential plans for a Phase 3 trial.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!